Hepatic encephalopathy (HE) is a prognostically relevant neuropsychiatric syndrome that occurs in the course of acute or chronic liver disease. Besides ascites and variceal bleeding, it is the most serious complication of decompensated liver cirrhosis. Ammonia and inflammation are major triggers for the appearance of HE, which in patients with liver cirrhosis involves pathophysiologically low-grade cerebral oedema with oxidative/nitrosative stress, inflammation and disturbances of oscillatory networks in the brain. Severity classification and diagnostic approaches regarding mild forms of HE are still a matter of debate. Current medical treatment predominantly involves lactulose and rifaximin following rigorous treatment of so-called known HE precipitating factors. New treatments based on an improved pathophysiological understanding are emerging.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $79.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Vilstrup, H. et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 60, 715–735 (2014).
Riggio, O. et al. High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology 42, 1158–1165 (2005).
Cordoba, J. et al. Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J. Hepatol. 60, 275–281 (2014).
Sawhney, R. et al. Role of ammonia, inflammation, and cerebral oxygenation in brain dysfunction of acute-on-chronic liver failure patients: Brain Dysfunction and ACLF. Liver Transpl. 22, 732–742 (2016).
Wright, G., Sharifi, Y., Jover-Cobos, M. & Jalan, R. The brain in acute on chronic liver failure. Metab. Brain Dis. 29, 965–973 (2014).
Jalan, R., Moreau, R. & Arroyo, V. Acute-on-chronic liver failure. Reply. N. Engl. J. Med. 383, 893–894 (2020).
Lauridsen, M. M. et al. Validation of a simple quality-of-life score for identification of minimal and prediction of overt hepatic encephalopathy. Hepatol. Commun. 4, 1353–1361 (2020).
Ladegaard Grønkjær, L., Hoppe Sehstedt, T., Norlyk, A. & Vilstrup, H. Overt hepatic encephalopathy experienced by individuals with cirrhosis: a qualitative interview study. Gastroenterol. Nurs. 41, 468–476 (2018).
Fabrellas, N. et al. Psychological burden of hepatic encephalopathy on patients and caregivers. Clin. Transl. Gastroenterol. 11, e00159 (2020).
Shrestha, D. et al. Factors affecting psychological burden on the informal caregiver of patients with cirrhosis: looking beyond the patient. J. Clin. Exp. Hepatol. 10, 9–16 (2020).
Rose, C. F. et al. Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy. J. Hepatol. 73, 1526–1547 (2020).
Wendon, J. et al. EASL clinical practical guidelines on the management of acute (fulminant) liver failure. J. Hepatol. 66, 1047–1081 (2017).
Nicoletti, V. et al. Hepatic encephalopathy in patients with non-cirrhotic portal hypertension: description, prevalence and risk factors. Dig. Liver Dis. 48, 1072–1077 (2016).
Kraglund, F., Jepsen, P., Amanavicius, N. & Aagaard, N. K. Long-term effects and complications of the transjugular intrahepatic portosystemic shunt: a single-centre experience. Scand. J. Gastroenterol. 54, 899–904 (2019).
Sepanlou, S. G. et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 5, 245–266 (2020).
Lauridsen, M. M., Jepsen, P. & Vilstrup, H. Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy. A comparative study of 154 patients with liver disease. Metab. Brain Dis. 26, 135–139 (2011).
Rathi, S. et al. Prevalence of minimal hepatic encephalopathy in patients with liver cirrhosis: a cross-sectional, clinicoepidemiological, multicenter, nationwide study in India: the PREDICT study. J. Clin. Exp. Hepatol. 9, 476–483 (2019).
Tapper, E. B., Henderson, J. B., Parikh, N. D., Ioannou, G. N. & Lok, A. S. Incidence of and risk factors for hepatic encephalopathy in a population-based cohort of Americans with cirrhosis. Hepatol. Commun. 3, 1510–1519 (2019).
Jepsen, P., Ott, P., Andersen, P. K., Sørensen, H. T. & Vilstrup, H. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 51, 1675–1682 (2009).
Moreau, R. et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 144, 1426–1437 (2013).
Hirode, G., Vittinghoff, E. & Wong, R. J. Increasing burden of hepatic encephalopathy among hospitalized adults: an analysis of the 2010–2014 national inpatient sample. Dig. Dis. Sci. 64, 1448–1457 (2019).
Di Pascoli, M. et al. Hospitalizations due to cirrhosis: clinical aspects in a large cohort of italian patients and cost analysis report. Dig. Dis. 35, 433–438 (2017).
Riggio, O. et al. A Model for predicting development of overt hepatic encephalopathy in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 13, 1346–1352 (2015).
Guevara, M. et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am. J. Gastroenterol. 104, 1382–1389 (2009).
Gil-Gómez, A. et al. Development and validation of a clinical-genetic risk score to predict hepatic encephalopathy in patients with liver cirrhosis. Am. J. Gastroenterol. 116, 1238–1247 (2021).
Yoo, H. Y., Edwin, D. & Thuluvath, P. J. Relationship of the model for end-stage liver disease (MELD) scale to hepatic encephalopathy, as defined by electroencephalography and neuropsychometric testing, and ascites. Am. J. Gastroenterol. 98, 1395–1399 (2003).
Praktiknjo, M. et al. Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. J. Hepatol. 72, 1140–1150 (2020).
Yin, X. et al. A nomogram to predict the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients. Sci. Rep. 10, 9381 (2020).
Zhou, Y. et al. PTFE-covered TIPS is an effective treatment for secondary preventing variceal rebleeding in cirrhotic patients with high risks. Eur. J. Gastroenterol. Hepatol. 32, 1235–1243 (2020).
Qi, X., Tian, Y., Zhang, W., Yang, Z. & Guo, X. Covered versus bare stents for transjugular intrahepatic portosystemic shunt: an updated meta-analysis of randomized controlled trials. Ther. Adv. Gastroenterol. 10, 32–41 (2016).
Nicoară-Farcău, O. et al. Preemptive TIPS Individual Data Metanalysis, International Variceal Bleeding Study and Baveno Cooperation Study groups. Effects of early placement of transjugular portosystemic shunts in patients with high-risk acute variceal bleeding: a meta-analysis of individual patient data. Gastroenterology 160, 193–205 (2021).
Jepsen, P., Watson, H., Andersen, P. K. & Vilstrup, H. Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients. J. Hepatol. 63, 1133–1138 (2015).
Ampuero, J. et al. Role of diabetes mellitus on hepatic encephalopathy. Metab. Brain Dis. 28, 277–279 (2012).
Vilar-Gomez, E. et al. Type 2 diabetes and metformin use associate with outcomes of patients with nonalcoholic steatohepatitis-related, child-pugh a cirrhosis. Clin. Gastroenterol. Hepatol. 19, 136–145.e6 (2021).
Elkrief, L. et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology 60, 823–831 (2014).
Jepsen, P., Christensen, J., Weissenborn, K., Watson, H. & Vilstrup, H. Epilepsy as a risk factor for hepatic encephalopathy in patients with cirrhosis: a cohort study. BMC Gastroenterol. 16, 77–77 (2016).
Nardelli, S. et al. Muscle alterations are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis. Hepatology 70, 1704–1713 (2019).
Shawcross, D. L., Davies, N. A., Williams, R. & Jalan, R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J. Hepatol. 40, 247–254 (2004).
Merli, M. et al. Increased risk of cognitive impairment in cirrhotic patients with bacterial infections. J. Hepatol. 59, 243–250 (2013).
Yuan, L.-T. et al. Multiple bacterial infections increase the risk of hepatic encephalopathy in patients with cirrhosis. PLoS ONE 13, e0197127 (2018).
Solé, C. et al. Alterations in gut microbiome in cirrhosis as assessed by quantitative metagenomics: relationship with acute-on-chronic liver failure and prognosis. Gastroenterology 160, 206–218.e13 (2021).
Bajaj, J. S. et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J. Hepatol. 60, 940–947 (2014).
Gupta, A. et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J. Hepatol. 53, 849–855 (2010).
Dam, G., Vilstrup, H., Watson, H. & Jepsen, P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology 64, 1265–1272 (2016).
Nardelli, S. et al. Proton pump inhibitors are associated with minimal and overt hepatic encephalopathy and increased mortality in patients with cirrhosis. Hepatology 70, 640–649 (2019).
Verma, N. et al. Dynamic assessments of hepatic encephalopathy and ammonia levels predict mortality in acute-on-chronic liver failure. Hepatol. Int. 15, 970–982 (2021).
Qvartskhava, N. et al. Hyperammonemia in gene-targeted mice lacking functional hepatic glutamine synthetase. Proc. Natl Acad. Sci. 112, 5521–5526 (2015).
DeMorrow, S., Cudalbu, C., Davies, N., Jayakumar, A. R. & Rose, C. F. 2021 ISHEN guidelines on animal models of hepatic encephalopathy. Liver Int. 41, 1474–1488 (2021).
Häussinger, D., Kircheis, G., Fischer, R., Schliess, F. & vom Dahl, S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J. Hepatol. 32, 1035–1038 (2000).
Cudalbu, C. & Taylor-Robinson, S. D. Brain edema in chronic hepatic encephalopathy. J. Clin. Exp. Hepatol. 9, 362–382 (2019).
Córdoba, J. et al. The development of low-grade cerebral edema in cirrhosis is supported by the evolution of 1H-magnetic resonance abnormalities after liver transplantation. J. Hepatol. 35, 598–604 (2001).
Llansola, M. et al. NMDA receptors in hyperammonemia and hepatic encephalopathy. Metab. Brain Dis. 22, 321–335 (2007).
Ott, P. & Larsen, F. S. Blood-brain barrier permeability to ammonia in liver failure: a critical reappraisal. Neurochem. Int. 44, 185–198 (2004).
Häussinger, D. & Blei, A. in Textbook of Hepatology 728–760 (Wiley-Blackwell Oxford, 2007).
Palomero-Gallagher, N. & Zilles, K. Neurotransmitter receptor alterations in hepatic encephalopathy: a review. Arch. Biochem. Biophys. 536, 109–121 (2013).
Williams, E., Chu, C. & DeMorrow, S. A critical review of bile acids and their receptors in hepatic encephalopathy. Anal. Biochem. 643, 114436 (2022).
Butterworth, R. F. Hepatic encephalopathy in cirrhosis: pathology and pathophysiology. Drugs 79, 17–21 (2019).
Butterworth, R. F. Neurosteroids in hepatic encephalopathy: novel insights and new therapeutic opportunities. J. Steroid Biochem. Mol. Biol. 160, 94–97 (2016).
Butterworth, R. F. Role of circulating neurotoxins in the pathogenesis of hepatic encephalopathy: potential for improvement following their removal by liver assist devices. Liver Int. 23 (Suppl. 3), 5–9 (2003).
Rivera-Mancía, S., Ríos, C. & Montes, S. Manganese accumulation in the CNS and associated pathologies. Biometals 24, 811–825 (2011).
Dejong, C. H. C., van de Poll, M. C. G., Soeters, P. B., Jalan, R. & Olde Damink, S. W. M. Aromatic amino acid metabolism during liver failure. J. Nutr. 137, 1579S–1585S (2007).
Bernardini, P. & Fischer, J. E. Amino acid imbalance and hepatic encephalopathy. Annu. Rev. Nutr. 2, 419–454 (1982).
Frieg, B., Görg, B., Gohlke, H. & Häussinger, D. Glutamine synthetase as a central element in hepatic glutamine and ammonia metabolism: novel aspects. Biol. Chem. 402, 1063–1072 (2021).
Häussinger, D. Nitrogen metabolism in liver: structural and functional organization and physiological relevance. Biochem. J. 267, 281–290 (1990).
Stoll, B., McNelly, S., Buscher, H. P. & Häussinger, D. Functional hepatocyte heterogeneity in glutamate, aspartate and alpha-ketoglutarate uptake: a histoautoradiographical study. Hepatology 13, 247–253 (1991).
Norenberg, M. D. The role of astrocytes in hepatic encephalopathy. Neurochem. Pathol. 6, 13–33 (1987).
Häussinger, D. et al. Proton magnetic resonance spectroscopy studies on human brain Myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology 107, 1475–1480 (1994).
Shah, N. J. et al. Quantitative cerebral water content mapping in hepatic encephalopathy. NeuroImage 41, 706–717 (2008).
Winterdahl, M. et al. Cerebral water content mapping in cirrhosis patients with and without manifest HE. Metab. Brain Dis. 34, 1071–1076 (2019).
Görg, B. et al. Oxidative stress markers in the brain of patients with cirrhosis and hepatic encephalopathy. Hepatology 52, 256–265 (2010).
Häussinger, D. & Görg, B. in Oxidative Stress: Eustress and Distress 669–693 (Elsevier, 2019).
Häussinger, D., Butz, M., Schnitzler, A. & Görg, B. Pathomechanisms in hepatic encephalopathy. Biol. Chem. 402, 1087–1102 (2021).
Lachmann, V., Görg, B., Bidmon, H. J., Keitel, V. & Häussinger, D. Precipitants of hepatic encephalopathy induce rapid astrocyte swelling in an oxidative stress dependent manner. Arch. Biochem. Biophys. 536, 143–151 (2013).
Schliess, F., Görg, B. & Häussinger, D. Pathogenetic interplay between osmotic and oxidative stress: the hepatic encephalopathy paradigm. Biol. Chem. 387, 1363–1370 (2006).
Görg, B. et al. Inflammatory cytokines induce protein tyrosine nitration in rat astrocytes. Arch. Biochem. Biophys. 449, 104–114 (2006).
Görg, B. Benzodiazepine-induced protein tyrosine nitration in rat astrocytes. Hepatology 37, 334–342 (2003).
Schliess, F., Foster, N., Görg, B., Reinehr, R. & Häussinger, D. Hypoosmotic swelling increases protein tyrosine nitration in cultured rat astrocytes. Glia 47, 21–29 (2004).
Häussinger, D. & Schliess, F. Pathogenetic mechanisms of hepatic encephalopathy. Gut 57, 1156–1165 (2008).
Rama Rao, K. V., Jayakumar, A. R., Tong, X., Alvarez, V. M. & Norenberg, M. D. Marked potentiation of cell swelling by cytokines in ammonia-sensitized cultured astrocytes. J. Neuroinflammation 7, 66 (2010).
Jayakumar, A. R., Tong, X. Y., Ospel, J. & Norenberg, M. D. Role of cerebral endothelial cells in the astrocyte swelling and brain edema associated with acute hepatic encephalopathy. Neuroscience 218, 305–316 (2012).
Rama Rao, K. V. & Norenberg, M. D. Glutamine in the pathogenesis of hepatic encephalopathy: the trojan horse hypothesis revisited. Neurochem. Res. 39, 593–598 (2013).
Zemtsova, I. et al. Microglia activation in hepatic encephalopathy in rats and humans. Hepatology 54, 204–215 (2011).
Bosoi, C. R. et al. Systemic oxidative stress is implicated in the pathogenesis of brain edema in rats with chronic liver failure. Free Radic. Biol. Med. 52, 1228–1235 (2012).
Nikolov, P. et al. Altered motor cortical plasticity in patients with hepatic encephalopathy: a paired associative stimulation study. Clin. Neurophysiol. 132, 2332–2341 (2021).
Butz, M. et al. Motor impairment in liver cirrhosis without and with minimal hepatic encephalopathy. Acta Neurol. Scand. 122, 27–35 (2009).
Schliess, F. et al. Ammonia induces MK-801-sensitive nitration and phosphorylation of protein tyrosine residues in rat astrocytes. FASEB J. 16, 739–741 (2002).
Mayer, M. L., Westbrook, G. L. & Guthrie, P. B. Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature 309, 261–263 (1984).
Kloda, A., Lua, L., Hall, R., Adams, D. J. & Martinac, B. Liposome reconstitution and modulation of recombinant N-methyl-D-aspartate receptor channels by membrane stretch. Proc. Natl Acad. Sci. USA 104, 1540–1545 (2007).
Görg, B. et al. Ammonia triggers exocytotic release of L-glutamate from cultured rat astrocytes. Glia 6, 691–705 (2010).
Reinehr, R. et al. Hypoosmotic swelling and ammonia increase oxidative stress by NADPH oxidase in cultured astrocytes and vital brain slices. Glia 55, 758–771 (2007).
Kruczek, C. et al. Hypoosmotic swelling affects zinc homeostasis in cultured rat astrocytes. Glia 57, 79–92 (2009).
Chastre, A., Jiang, W., Desjardins, P. & Butterworth, R. F. Ammonia and proinflammatory cytokines modify expression of genes coding for astrocytic proteins implicated in brain edema in acute liver failure. Metab. Brain Dis. 25, 17–21 (2010).
Sinke, A. P. et al. NFkappaB in the mechanism of ammonia-induced astrocyte swelling in culture. J. Neurochem. 106, 2302–2311 (2008).
Brück, J. et al. Locomotor impairment and cerebrocortical oxidative stress in portal vein ligated rats in vivo. J. Hepatol. 54, 251–257 (2011).
Suárez, I., Bodega, G., Rubio, M., Felipo, V. & Fernández, B. Neuronal and inducible nitric oxide synthase expression in the rat cerebellum following portacaval anastomosis. Brain Res. 1047, 205–213 (2005).
Suárez, I., Bodega, G., Arilla, E., Felipo, V. & Fernández, B. The expression of nNOS, iNOS and nitrotyrosine is increased in the rat cerebral cortex in experimental hepatic encephalopathy. Neuropathol. Appl. Neurobiol. 32, 594–604 (2006).
Görg, B., Bidmon, H.-J. & Häussinger, D. Gene expression profiling in the cerebral cortex of patients with cirrhosis with and without hepatic encephalopathy. Hepatology 57, 2436–2447 (2013).
Kosenko, E. A. et al. Portacaval shunting causes differential mitochondrial superoxide production in brain regions. Free Radic. Biol. Med. 113, 109–118 (2017).
Widmer, R., Kaiser, B., Engels, M., Jung, T. & Grune, T. Hyperammonemia causes protein oxidation and enhanced proteasomal activity in response to mitochondria-mediated oxidative stress in rat primary astrocytes. Arch. Biochem. Biophys. 464, 1–11 (2007).
Cardona, C. et al. Expression of Gls and Gls2 glutaminase isoforms in astrocytes. Glia 63, 365–382 (2014).
Jördens, M. S. et al. Multidrug resistance-associated protein 4 expression in ammonia-treated cultured rat astrocytes and cerebral cortex of cirrhotic patients with hepatic encephalopathy. Glia 63, 2092–2105 (2015).
Kruczek, C. et al. Ammonia increases nitric oxide, free Zn2+, and metallothionein mRNA expression in cultured rat astrocytes. Biol. Chem. 392, 1155–1165 (2011).
Lavoie, J., Layrargues, G. P. & Butterworth, R. F. Increased densities of peripheral-type benzodiazepine receptors in brain autopsy samples from cirrhotic patients with hepatic encephalopathy. Hepatology 11, 874–878 (1990).
Ahboucha, S. et al. Indomethacin improves locomotor deficit and reduces brain concentrations of neuroinhibitory steroids in rats following portacaval anastomosis. Neurogastroenterol. Motil. 20, 949–957 (2008).
Ahboucha, S., Pomier-Layrargues, G., Mamer, O. & Butterworth, R. F. Increased levels of pregnenolone and its neuroactive metabolite allopregnanolone in autopsied brain tissue from cirrhotic patients who died in hepatic coma. Neurochem. Int. 49, 372–378 (2006).
Keitel, V. et al. The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. Glia 58, 1794–1805 (2010).
Oenarto, J. et al. Ammonia-induced miRNA expression changes in cultured rat astrocytes. Sci. Rep. 6, 18493–18493 (2016).
Görg, B. et al. O-GlcNAcylation-dependent upregulation of HO1 triggers ammonia-induced oxidative stress and senescence in hepatic encephalopathy. J. Hepatol. 71, 930–941 (2019).
Jayakumar, A. R. et al. Na-K-Cl Cotransporter-1 in the mechanism of ammonia-induced astrocyte swelling. J. Biol. Chem. 283, 33874–33882 (2008).
Vaquero, J., Chung, C., Cahill, M. & Blei, A. Pathogenesis of hepatic encephalopathy in acute liver failure. Semin. Liver Dis. 23, 259–270 (2003).
Carbonero-Aguilar, P. et al. Brain biomolecules oxidation in portacaval-shunted rats. Liver Int. 31, 964–969 (2011).
Bai, Y., Wang, Y. & Yang, Y. Hepatic encephalopathy changes mitochondrial dynamics and autophagy in the substantia nigra. Metab. Brain Dis. 33, 1669–1678 (2018).
Lu, K. et al. Hepatic encephalopathy is linked to alterations of autophagic flux in astrocytes. EBioMedicine 48, 539–553 (2019).
Luo, S., Au Yeung, S. L., Zhao, J. V., Burgess, S. & Schooling, C. M. Association of genetically predicted testosterone with thromboembolism, heart failure, and myocardial infarction: mendelian randomisation study in UK Biobank. BMJ https://doi.org/10.1136/bmj.l476 (2019).
Gelpi, E. et al. The autophagic marker p62 highlights Alzheimer type II astrocytes in metabolic/hepatic encephalopathy. Neuropathology 40, 358–366 (2020).
Frank, M. et al. Mitophagy is triggered by mild oxidative stress in a mitochondrial fission dependent manner. Biochim. Biophys. Acta 1823, 2297–2310 (2012).
Görg, B., Karababa, A., Shafigullina, A., Bidmon, H. J. & Häussinger, D. Ammonia-induced senescence in cultured rat astrocytes and in human cerebral cortex in hepatic encephalopathy. Glia 63, 37–50 (2014).
Drews, L. et al. Ammonia inhibits energy metabolism in astrocytes in a rapid and glutamate dehydrogenase 2-dependent manner. Dis. Model. Mech. 13, dmm047134 (2020).
Rama Rao, K. V. & Norenberg, M. D. Brain energy metabolism and mitochondrial dysfunction in acute and chronic hepatic encephalopathy. Neurochem. Int. 60, 697–706 (2012).
Zimmermann, M. & Reichert, A. S. Rapid metabolic and bioenergetic adaptations of astrocytes under hyperammonemia – a novel perspective on hepatic encephalopathy. Biol. Chem. 402, 1103–1113 (2021).
Görg, B. et al. Ammonia induces RNA oxidation in cultured astrocytes and brain in vivo. Hepatology 48, 567–579 (2008).
Chan, H. Effects of ammonia on glutamate transporter (GLAST) protein and mRNA in cultured rat cortical astrocytes. Neurochem. Int. 37, 243–248 (2000).
Zhou, B.-G. & Norenberg, M. D. Ammonia downregulates GLAST mRNA glutamate transporter in rat astrocyte cultures. Neurosci. Lett. 276, 145–148 (1999).
Limbad, C. et al. Astrocyte senescence promotes glutamate toxicity in cortical neurons. PLoS ONE 15, e0227887–e0227887 (2020).
Bajaj, J. S. et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology 138, 2332–2340 (2010).
Riggio, O. et al. Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy. Clin. Gastroenterol. Hepatol. 9, 181–183 (2011).
Sobczyk, K., Jördens, M. S., Karababa, A., Görg, B. & Häussinger, D. Ephrin/ephrin receptor expression in ammonia-treated rat astrocytes and in human cerebral cortex in hepatic encephalopathy. Neurochem. Res. 40, 274–283 (2014).
Schrimpf, A. et al. Hyperammonemia-induced changes in the cerebral transcriptome and proteome. Anal. Biochem. 641, 114548 (2022).
Cabrera-Pastor, A. et al. Peripheral inflammation induces neuroinflammation that alters neurotransmission and cognitive and motor function in hepatic encephalopathy: underlying mechanisms and therapeutic implications. Acta Physiol. 226, e13270 (2019).
Coltart, I., Tranah, T. H. & Shawcross, D. L. Inflammation and hepatic encephalopathy. Arch. Biochem. Biophys. 536, 189–196 (2013).
Felipo, V. et al. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. Metab. Brain Dis. 27, 51–58 (2011).
Pozdeev, V. I. et al. TNFα induced up-regulation of Na+,K+,2Cl− cotransporter NKCC1 in hepatic ammonia clearance and cerebral ammonia toxicity. Sci. Rep. 7, 7938 (2017).
Rodrigo, R. et al. Hyperammonemia induces neuroinflammation that contributes to cognitive impairment in rats with hepatic encephalopathy. Gastroenterology 139, 675–684 (2010).
Balzano, T. et al. Chronic hyperammonemia induces peripheral inflammation that leads to cognitive impairment in rats: reversed by anti-TNF-α treatment. J. Hepatol. 73, 582–592 (2020).
Görg, B., Wettstein, M., Metzger, S., Schliess, F. & Häussinger, D. Lipopolysaccharide-induced tyrosine nitration and inactivation of hepatic glutamine synthetase in the rat. Hepatology 41, 1065–1073 (2005).
Bajaj, J. S. et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 303, G675–G685 (2012).
Dhiman, R. K. Gut microbiota, inflammation and hepatic encephalopathy: a puzzle with a solution in sight. J. Clin. Exp. Hepatol. 2, 207–210 (2012).
Acharya, C. & Bajaj, J. S. Altered microbiome in patients with cirrhosis and complications. Clin. Gastroenterol. Hepatol. 17, 307–321 (2019).
Iebba, V. et al. Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy. Sci. Rep. 8, 8210–8210 (2018).
Montoliu, C. et al. IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy. J. Clin. Gastroenterol. 43, 272–279 (2009).
Azhari, H. & Swain, M. G. Role of peripheral inflammation in hepatic encephalopathy. J. Clin. Exp. Hepatol. 8, 281–285 (2018).
Dadsetan, S. et al. Reducing peripheral inflammation with infliximab reduces neuroinflammation and improves cognition in rats with hepatic encephalopathy. Front. Mol. Neurosci. 9, 106–106 (2016).
Mangas-Losada, A. et al. Minimal hepatic encephalopathy is associated with expansion and activation of CD4+CD28−, Th22 and Tfh and B lymphocytes. Sci. Rep. 7, 6683–6683 (2017).
Shen, J. et al. The role of exosomes in hepatitis, liver cirrhosis and hepatocellular carcinoma. J. Cell. Mol. Med. 21, 986–992 (2017).
Thietart, S. & Rautou, P.-E. Extracellular vesicles as biomarkers in liver diseases: a clinician’s point of view. J. Hepatol. 73, 1507–1525 (2020).
Eguchi, A. & Feldstein, A. E. Extracellular vesicles in non-alcoholic and alcoholic fatty liver diseases. Liver Res. 2, 30–34 (2018).
Izquierdo-Altarejos, P., Cabrera-Pastor, A., Gonzalez-King, H., Montoliu, C. & Felipo, V. Extracellular vesicles from hyperammonemic rats induce neuroinflammation and motor incoordination in control rats. Cells 9, 572 (2020).
McMillin, M. et al. Bile acid-mediated sphingosine-1-phosphate receptor 2 signaling promotes neuroinflammation during hepatic encephalopathy in mice. Front. Cell. Neurosci. 11, 191–191 (2017).
D’Mello, C., Le, T. & Swain, M. G. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J. Neurosci. 29, 2089–2102 (2009).
Balzano, T. et al. Rifaximin prevents T-lymphocytes and macrophages infiltration in cerebellum and restores motor incoordination in rats with mild liver damage. Biomedicines 9, 1002 (2021).
Dennis, C. V. et al. Microglial proliferation in the brain of chronic alcoholics with hepatic encephalopathy. Metab. Brain Dis. 29, 1027–1039 (2014).
Balzano, T. et al. The cerebellum of patients with steatohepatitis shows lymphocyte infiltration, microglial activation and loss of purkinje and granular neurons. Sci. Rep. 8, 3004–3004 (2018).
Cauli, O., Mansouri, M. T., Agusti, A. & Felipo, V. Hyperammonemia increases GABAergic tone in the cerebellum but decreases it in the rat cortex. Gastroenterology 136, 1359–1367.e2 (2009).
Arenas, Y. M., Cabrera-Pastor, A., Juciute, N., Mora-Navarro, E. & Felipo, V. Blocking glycine receptors reduces neuroinflammation and restores neurotransmission in cerebellum through ADAM17-TNFR1-NF-κβ pathway. J. Neuroinflammation 17, 269 (2020).
Yurdaydin, C. et al. Increased serotoninergic and noradrenergic activity in hepatic encephalopathy in rats with thioacetamide-induced acute liver failure. Hepatology 12, 695–700 (1990).
García-Ayllón, M.-S. et al. Brain cholinergic impairment in liver failure. Brain J. Neurol. 131, 2946–2956 (2008).
Chen, B. et al. The critical role of hippocampal dopamine in the pathogenesis of hepatic encephalopathy. Physiol. Res. 70, 101–110 (2021).
Hassan, S. S. et al. Cerebellar inhibition in hepatic encephalopathy. Clin. Neurophysiol. 130, 886–892 (2019).
Groiss, S. J. et al. GABA-ergic tone hypothesis in hepatic encephalopathy–revisited. Clin. Neurophysiol. 130, 911–916 (2019).
Nardone, R. et al. Intracortical inhibitory and excitatory circuits in subjects with minimal hepatic encephalopathy: a TMS study. Metab. Brain Dis. 31, 1065–1070 (2016).
Montagnese, S. et al. A pilot study of golexanolone, a new GABA-A receptor-modulating steroid antagonist, in patients with covert hepatic encephalopathy. J. Hepatol. 75, 98–107 (2021).
Taoro-González, L. et al. Differential role of interleukin-1β in neuroinflammation-induced impairment of spatial and nonspatial memory in hyperammonemic rats. FASEB J. 33, 9913–9928 (2019).
Schnitzler, A. & Gross, J. Normal and pathological oscillatory communication in the brain. Nat. Rev. Neurosci. 6, 285–296 (2005).
Butz, M., May, E. S., Häussinger, D. & Schnitzler, A. The slowed brain: cortical oscillatory activity in hepatic encephalopathy. Arch. Biochem. Biophys. 536, 197–203 (2013).
Timmermann, L., Gross, J., Kircheis, G., Häussinger, D. & Schnitzler, A. Cortical origin of mini-asterixis in hepatic encephalopathy. Neurology 58, 295–298 (2002).
Timmermann, L. et al. Mini-asterixis in hepatic encephalopathy induced by pathologic thalamo-motor-cortical coupling. Neurology 61, 689–692 (2003).
Timmermann, L. et al. Impaired cerebral oscillatory processing in hepatic encephalopathy. Clin. Neurophysiol. 119, 265–272 (2008).
Kahlbrock, N. et al. Lowered frequency and impaired modulation of gamma band oscillations in a bimodal attention task are associated with reduced critical flicker frequency. NeuroImage 61, 216–227 (2012).
Fries, P. Neuronal gamma-band synchronization as a fundamental process in cortical computation. Annu. Rev. Neurosci. 32, 209–224 (2009).
May, E. S. et al. Hepatic encephalopathy is associated with slowed and delayed stimulus-associated somatosensory alpha activity. Clin. Neurophysiol. 125, 2427–2435 (2014).
Lazar, M. et al. Impaired tactile temporal discrimination in patients with hepatic encephalopathy. Front. Psychol. 9, 2059 (2018).
Baumgarten, T. J., Schnitzler, A. & Lange, J. Beta oscillations define discrete perceptual cycles in the somatosensory domain. Proc. Natl Acad. Sci. USA 112, 12187–12192 (2015).
Kullmann, F. et al. Brain electrical activity mapping of EEG for the diagnosis of (sub)clinical hepatic encephalopathy in chronic liver disease. Eur. J. Gastroenterol. Hepatol. 13, 513–522 (2001).
Baumgarten, T. J. et al. Connecting occipital alpha band peak frequency, visual temporal resolution, and occipital GABA levels in healthy participants and hepatic encephalopathy patients. NeuroImage Clin. 20, 347–356 (2018).
VanRullen, R. Perceptual cycles. Trends Cogn. Sci. 20, 723–735 (2016).
Hadjihambi, A. et al. Impaired brain glymphatic flow in experimental hepatic encephalopathy. J. Hepatol. 70, 40–49 (2019).
Claeys, W. et al. The neurogliovascular unit in hepatic encephalopathy. JHEP Rep. Innov. Hepatol. 3, 100352 (2021).
Costa, R. & Montagnese, S. The role of astrocytes in generating circadian rhythmicity in health and disease. J. Neurochem. 157, 42–52 (2021).
Jindal, A. & Jagdish, R. K. Sarcopenia: ammonia metabolism and hepatic encephalopathy. Clin. Mol. Hepatol. 25, 270–279 (2019).
García, P. S., Cabbabe, A., Kambadur, R., Nicholas, G. & Csete, M. Brief-reports: elevated myostatin levels in patients with liver disease: a potential contributor to skeletal muscle wasting. Anesth. Analg. 111, 707–709 (2010).
Conn, H. O. et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. Gastroenterology 72, 573–583 (1977).
Conn, H. & Lieberthal, M. in The Hepatic Coma Syndromes and Lactulose 5–8 (Williams & Wilkins, 1979).
Reuter, B. et al. Assessment of the spectrum of hepatic encephalopathy: a multicenter study. Liver Transpl. 24, 587–594 (2018).
Bajaj, J. S. et al. Review article: the design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment. Pharmacol. Ther. 33, 739–747 (2011).
Montagnese, S. et al. Hepatic encephalopathy 2018: a clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Dig. Liver Dis. 51, 190–205 (2019).
Montagnese, S. et al. Covert hepatic encephalopathy: agreement and predictive validity of different indices. World J. Gastroenterol. 20, 15756–15762 (2014).
Thomsen, K. L., Macnaughtan, J., Tritto, G., Mookerjee, R. P. & Jalan, R. Clinical and pathophysiological characteristics of cirrhotic patients with grade 1 and minimal hepatic encephalopathy. PLoS ONE 11, e0146076 (2016).
Romero-Gómez, M., Boza, F., García-Valdecasas, M. S., García, E. & Aguilar-Reina, J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am. J. Gastroenterol. 96, 2718–2723 (2001).
Schomerus, H. & Hamster, W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab. Brain Dis. 16, 37–41 (2001).
Kircheis, G. et al. Hepatic encephalopathy and fitness to drive. Gastroenterology 137, 1706–1715.e9 (2009).
Kircheis, G., Hilger, N. & Häussinger, D. Value of critical flicker frequency and psychometric hepatic encephalopathy score in diagnosis of low-grade hepatic encephalopathy. Gastroenterology 146, 961–969.e11 (2014).
Häussinger, D. et al. in Hepatic Encephalopathy and Nitrogen Metabolism 423–432 (Springer Dordrecht, 2006).
Weissenborn, K., Heidenreich, S., Ennen, J., Rückert, N. & Hecker, H. Attention deficits in minimal hepatic encephalopathy. Metab. Brain Dis. 16, 13–19 (2001).
Campagna, F. et al. The animal naming test: an easy tool for the assessment of hepatic encephalopathy. Hepatology 66, 198–208 (2017).
Lauridsen, M. M., Grønbæk, H., Næser, E. B., Leth, S. T. & Vilstrup, H. Gender and age effects on the continuous reaction times method in volunteers and patients with cirrhosis. Metab. Brain Dis. 27, 559–565 (2012).
Lauridsen, M. M., Thiele, M., Kimer, N. & Vilstrup, H. The continuous reaction times method for diagnosing, grading, and monitoring minimal/covert hepatic encephalopathy. Metab. Brain Dis. 28, 231–234 (2013).
Bajaj, J. S. et al. Inhibitory control test is a simple method to diagnose minimal hepatic encephalopathy and predict development of overt hepatic encephalopathy. Am. J. Gastroenterol. 102, 754–760 (2007).
Amodio, P. et al. Improving the inhibitory control task to detect minimal hepatic encephalopathy. Gastroenterology 139, 510–518.e2 (2010).
Bajaj, J. S. et al. The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology 58, 1122–1132 (2013).
Amodio, P. et al. Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology 29, 1662–1667 (1999).
Amodio, P. et al. Spectral versus visual EEG analysis in mild hepatic encephalopathy. Clin. Neurophysiol. 110, 1334–1344 (1999).
Schiff, S. et al. A low-cost, user-friendly electroencephalographic recording system for the assessment of hepatic encephalopathy. Hepatology 63, 1651–1659 (2016).
Kircheis, G., Wettstein, M., Timmermann, L., Schnitzler, A. & Häussinger, D. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 35, 357–366 (2002).
Romero-Gómez, M. Critical flicker frequency: it is time to break down barriers surrounding minimal hepatic encephalopathy. J. Hepatol. 47, 10–11 (2007).
Kircheis, G. et al. Diagnostic and prognostic values of critical flicker frequency determination as new diagnostic tool for objective HE evaluation in patients undergoing TIPS implantation. Eur. J. Gastroenterol. Hepatol. 21, 1383–1394 (2009).
Berlioux, P. et al. Pre-transjugular intrahepatic portosystemic shunts (TIPS) prediction of post-TIPS overt hepatic encephalopathy: the critical flicker frequency is more accurate than psychometric tests. Hepatology 59, 622–629 (2013).
Romero-Gómez, M. et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 45, 879–885 (2007).
Ampuero, J. et al. Minimal hepatic encephalopathy and critical flicker frequency are associated with survival of patients with cirrhosis. Gastroenterology 149, 1483–1489 (2015).
Bandookwala, M. & Sengupta, P. 3-Nitrotyrosine: a versatile oxidative stress biomarker for major neurodegenerative diseases. Int. J. Neurosci. 130, 1047–1062 (2020).
Montoliu, C. et al. 3-nitro-tyrosine as a peripheral biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis. Am. J. Gastroenterol. 106, 1629–1637 (2011).
Gairing, S. J. et al. Evaluation of IL-6 for stepwise diagnosis of minimal hepatic encephalopathy in patients with liver cirrhosis. Hepatol. Commun. https://doi.org/10.1002/hep4.1883 (2022).
Labenz, C. et al. Raised serum interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy. Aliment. Pharmacol. Ther. 50, 1112–1119 (2019).
Quero Guillén, J. C. & Herrerías Gutiérrez, J. M. Diagnostic methods in hepatic encephalopathy. Clin. Chim. Acta 365, 1–8 (2006).
Grover, V. B. Current and future applications of magnetic resonance imaging and spectroscopy of the brain in hepatic encephalopathy. World J. Gastroenterol. 12, 2969 (2006).
Pagani, E., Bizzi, A., Di Salle, F., De Stefano, N. & Filippi, M. Basic concepts of advanced MRI techniques. Neurol. Sci. 29, 290–295 (2008).
Berding, G. et al. Radiotracer imaging studies in hepatic encephalopathy: ISHEN practice guidelines. Liver Int. 29, 621–628 (2009).
Smith, S. M. et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. NeuroImage 17, 479–489 (2002).
Patel, N., White, S., Dhanjal, N. S., Oatridge, A. & Taylor-Robinson, S. D. Changes in brain size in hepatic encephalopathy: a coregistered MRI study. Metab. Brain Dis. 19, 431–445 (2004).
Taylor-Robinson, S. D. et al. MR imaging of the basal ganglia in chronic liver disease: correlation of T1-weighted and magnetisation transfer contrast measurements with liver dysfunction and neuropsychiatric status. Metab. Brain Dis. 10, 175–188 (1995).
Kumar, R. et al. Voxel-based diffusion tensor magnetic resonance imaging evaluation of low-grade hepatic encephalopathy. J. Magn. Reson. Imaging 27, 1061–1068 (2008).
Miese, F. et al. 1H-MR spectroscopy, magnetization transfer, and diffusion-weighted imaging in alcoholic and nonalcoholic patients with cirrhosis with hepatic encephalopathy. AJNR Am. J. Neuroradiol. 27, 1019–1026 (2006).
McPhail, M. J. W. & Taylor-Robinson, S. D. The role of magnetic resonance imaging and spectroscopy in hepatic encephalopathy. Metab. Brain Dis. 25, 65–72 (2010).
Zafiris, O. et al. Neural mechanism underlying impaired visual judgement in the dysmetabolic brain: an fMRI study. NeuroImage 22, 541–552 (2004).
Cox, I. J. Development and applications of in vivo clinical magnetic resonance spectroscopy. Prog. Biophys. Mol. Biol. 65, 45–81 (1996).
Zhang, L. J., Yang, G., Yin, J., Liu, Y. & Qi, J. Neural mechanism of cognitive control impairment in patients with hepatic cirrhosis: a functional magnetic resonance imaging study. Acta Radiol. 48, 577–587 (2007).
Broyd, S. J. et al. Default-mode brain dysfunction in mental disorders: a systematic review. Neurosci. Biobehav. Rev. 33, 279–296 (2009).
Rovira, A., Grivé, E., Pedraza, S., Rovira, A. & Alonso, J. Magnetization transfer ratio values and proton MR spectroscopy of normal-appearing cerebral white matter in patients with liver cirrhosis. AJNR Am. J. Neuroradiol. 22, 1137–1142 (2001).
Laubenberger, J. et al. Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis. Gastroenterology 112, 1610–1616 (1997).
McPhail, M. J. W., Patel, N. R. & Taylor-Robinson, S. D. Brain imaging and hepatic encephalopathy. Clin. Liver Dis. 16, 57–72 (2012).
Grover, V. P. B. et al. A longitudinal study of patients with cirrhosis treated with L-ornithine L-aspartate, examined with magnetization transfer, diffusion-weighted imaging and magnetic resonance spectroscopy. Metab. Brain Dis. 32, 77–86 (2016).
Taylor-Robinson, S. D., Buckley, C., Changani, K. K., Hodgson, H. J. F. & Bell, J. D. Cerebral proton and phosphorus-31 magnetic resonance spectroscopy in patients with subclinical hepatic encephalopathy. Liver Int. 19, 389–398 (1999).
Patwardhan, V. R. et al. Serum ammonia is associated with transplant-free survival in hospitalized patients with acutely decompensated cirrhosis [corrected]. J. Clin. Gastroenterol. 50, 345–350 (2016).
Vierling, J. M. et al. Fasting blood ammonia predicts risk and frequency of hepatic encephalopathy episodes in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 14, 903–906.e1 (2016).
Shalimar et al. Prognostic role of ammonia in patients with cirrhosis. Hepatology 70, 982–994 (2019).
Clemmesen, J. O. et al. Hepatic blood flow and splanchnic oxygen consumption in patients with liver failure. Effect of high-volume plasmapheresis. Hepatology 29, 347–355 (1999).
Bhatia, V., Singh, R. & Acharya, S. K. Predictive value of arterial ammonia for complications and outcome in acute liver failure. Gut 55, 98–104 (2006).
Rose, C. F., Jalan, R. & Shawcross, D. L. Erroneous ammonia measurement is not synonymous with a lack of efficacy of ammonia-lowering therapies in hepatic encephalopathy. Clin. Gastroenterol. Hepatol. 19, 2456–2457 (2021).
Kramer, L. et al. Partial pressure of ammonia versus ammonia in hepatic encephalopathy. Hepatology 31, 30–34 (2000).
Drolz, A. et al. Clinical impact of arterial ammonia levels in ICU patients with different liver diseases. Intensive Care Med. 39, 1227–1237 (2013).
Huizenga, J. R., Gips, C. H., Conn, H. O. & Jansen, P. L. Determination of ammonia in ear-lobe capillary blood is an alternative to arterial blood ammonia. Clin. Chim. Acta Int. J. Clin. Chem. 239, 65–70 (1995).
Bersagliere, A. et al. Ammonia-related changes in cerebral electrogenesis in healthy subjects and patients with cirrhosis. Clin. Neurophysiol. 124, 492–496 (2013).
Hartmann, I. J. C. et al. The prognostic significance of subclinical hepatic encephalopathy. Am. J. Gastroenterol. 95, 2029–2034 (2000).
Patidar, K. R. et al. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am. J. Gastroenterol. 109, 1757–1763 (2014).
Flud, C. R. & Duarte-Rojo, A. Prognostic implications of minimal/covert hepatic encephalopathy: large-scale validation cohort studies. J. Clin. Exp. Hepatol. 9, 112–116 (2019).
Bustamante, J. et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J. Hepatol. 30, 890–895 (1999).
D’Amico, G., Garcia-Tsao, G. & Pagliaro, L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol. 44, 217–231 (2006).
Lucidi, C. et al. Hepatic encephalopathy expands the predictivity of model for end-stage liver disease in liver transplant setting: evidence by means of 2 independent cohorts. Liver Transpl. 22, 1333–1342 (2016).
López-Franco, Ó. et al. Cognitive impairment after resolution of hepatic encephalopathy: a systematic review and meta-analysis. Front. Neurosci. 15, 579263 (2021).
Matsumoto, S. et al. Urea cycle disorders-update. J. Hum. Genet. 64, 833–847 (2019).
Häberle, J. et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision. J. Inherit. Metab. Dis. 42, 1192–1230 (2019).
Plauth, M. et al. ESPEN guideline on clinical nutrition in liver disease. Clin. Nutr. 38, 485–521 (2019).
Amodio, P. et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International society for hepatic encephalopathy and nitrogen metabolism consensus. Hepatology 58, 325–336 (2013).
Yoshiji, H. et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. J. Gastroenterol. 56, 593–619 (2021).
European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease. J. Hepatol. 70, 172–193 (2019).
Tsien, C. D., McCullough, A. J. & Dasarathy, S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J. Gastroenterol. Hepatol. 27, 430–441 (2012).
Maharshi, S., Sharma, B. C., Sachdeva, S., Srivastava, S. & Sharma, P. Efficacy of nutritional therapy for patients with cirrhosis and minimal hepatic encephalopathy in a randomized trial. Clin. Gastroenterol. Hepatol. 14, 454–460.e3 (2016).
Takuma, Y., Nouso, K., Makino, Y., Hayashi, M. & Takahashi, H. Clinical trial: oral zinc in hepatic encephalopathy. Aliment. Pharmacol. Ther. 32, 1080–1090 (2010).
Bruyneel, M. & Sersté, T. Sleep disturbances in patients with liver cirrhosis: prevalence, impact, and management challenges. Nat. Sci. Sleep 10, 369–375 (2018).
Riggio, O., Nardelli, S., Gioia, S., Lucidi, C. & Merli, M. Management of hepatic encephalopathy as an inpatient. Clin. Liver Dis. 5, 79–82 (2015).
Davuluri, G. et al. Hyperammonaemia-induced skeletal muscle mitochondrial dysfunction results in cataplerosis and oxidative stress. J. Physiol. 594, 7341–7360 (2016).
Dasarathy, S. & Hatzoglou, M. Hyperammonemia and proteostasis in cirrhosis. Curr. Opin. Clin. Nutr. Metab. Care 21, 30–36 (2018).
Dam, G., Aamann, L., Vistrup, H. & Gluud, L. L. The role of branched chain amino acids in the treatment of hepatic encephalopathy. J. Clin. Exp. Hepatol. 8, 448–451 (2018).
Gluud, L. L. et al. in Cochrane Database of Systematic Reviews (John Wiley & Sons, Ltd., 2015).
Lai, J. C. & Tandon, P. Improving nutritional status in patients with cirrhosis. Am. J. Gastroenterol. 113, 1574–1576 (2018).
Sharma, B. C., Sharma, P., Agrawal, A. & Sarin, S. K. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 137, 885–891, 891.e1 (2009).
Agrawal, A., Sharma, B. C., Sharma, P. & Sarin, S. K. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am. J. Gastroenterol. 107, 1043–1050 (2012).
Dhiman, R. K. et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology 147, 1327–1337.e3 (2014).
Bass, N. M. et al. Rifaximin treatment in hepatic encephalopathy. N. Engl. J. Med. 362, 1071–1081 (2010).
Mullen, K. D. et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin. Gastroenterol. Hepatol. 12, 1390–1397.e2 (2014).
Gluud, L. L., Vilstrup, H. & Morgan, M. Y. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.cd003044.pub3 (2016).
Kimer, N., Krag, A., Møller, S., Bendtsen, F. & Gluud, L. L. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment. Pharmacol. Ther. 40, 123–132 (2014).
Bajaj, J. S. et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS ONE 8, e60042–e60042 (2013).
DuPont, H. L. Review article: the antimicrobial effects of rifaximin on the gut microbiota. Aliment. Pharmacol. Ther. 43, 3–10 (2015).
Goh, E. T. et al. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst. Rev. 5, CD012410 (2018).
Butterworth, R. F. & McPhail, M. J. W. L-Ornithine L-aspartate (LOLA) for hepatic encephalopathy in cirrhosis: results of randomized controlled trials and meta-analyses. Drugs 79, 31–37 (2019).
Naeshiro, N. et al. Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: long-term outcomes in 14 patients. Hepatol. Res. 44, 740–749 (2014).
Lv, Y. et al. Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: a randomized controlled trial. Hepatology https://doi.org/10.1002/hep.32453 (2022).
Álvarez-López, P. et al. Spontaneous portosystemic shunt embolization in liver transplant recipients with recurrent hepatic encephalopathy. Ann. Hepatol. 27, 100687 (2022).
Temmerman, F., Laleman, W., Maleux, G. & Nevens, F. Treatment of recurrent severe hepatic encephalopathy in patients with large porto-collaterals shunts or transjugular portosystemic shunt. Acta Gastroenterol. Belg. 83, 67–71 (2020).
Laleman, W. et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology 57, 2448–2457 (2013).
Rahimi, R. S., Singal, A. G., Cuthbert, J. A. & Rockey, D. C. Lactulose vs polyethylene Glycol 3350-electrolyte solution for treatment of overt hepatic encephalopathy. JAMA Intern. Med. 174, 1727 (2014).
Bajaj, J. S. et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology 66, 1727–1738 (2017).
Mullish, B. H., McDonald, J. A. K., Thursz, M. R. & Marchesi, J. R. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology 66, 1354–1355 (2017).
Kurtz, C. B. et al. An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. Sci. Transl. Med. 11, eaau7975 (2019).
Synlogic. Synlogic discontinues development of SYNB1020 to treat hyperammonemia. Synlogic https://investor.synlogictx.com/news-releases/news-release-details/synlogic-discontinues-development-synb1020-treat-hyperammonemia (2019).
Dalal, R., McGee, R. G., Riordan, S. M. & Webster, A. C. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst. Rev. 2, CD008716 (2017).
Wiest, R., Albillos, A., Trauner, M., Bajaj, J. S. & Jalan, R. Targeting the gut-liver axis in liver disease. J. Hepatol. 67, 1084–1103 (2017).
Jalan, R., Wright, G., Davies, N. A. & Hodges, S. J. l-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy. Med. Hypotheses 69, 1064–1069 (2007).
Rahimi, R. S. et al. Efficacy and safety of ornithine phenylacetate for treating overt hepatic encephalopathy in a randomized trial. Clin. Gastroenterol. Hepatol. 19, 2626–2635.e7 (2021).
Safadi, R. et al. Pharmacokinetics/pharmacodynamics of L-ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes. Clin. Transl. Sci. https://doi.org/10.1111/cts.13257 (2022).
Maestri, N. E., Brusilow, S. W., Clissold, D. B. & Bassett, S. S. Long-term treatment of girls with ornithine transcarbamylase deficiency. N. Engl. J. Med. 335, 855–859 (1996).
Butterworth, R. F. Ammonia removal by metabolic scavengers for the prevention and treatment of hepatic encephalopathy in cirrhosis. Drugs R. D. 21, 123–132 (2021).
Rockey, D. C. et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology 59, 1073–1083 (2014).
Uschner, F. et al. Safety and preliminary efficacy and pharmocokinetics of intraperitoneal VS-01 infusions in patients with decompensated liver cirrhosis: a first in human open label phase 1b clinical trial. Hepatology 74, 139A (2021).
Hassanein, T. I. et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 46, 1853–1862 (2007).
Agarwal, B., Saliba, F. & Tomescu, D. A multi-centre, randomized controlled study, to evaluate the safety and performance of the DIALIVE liver dialysis device in patients with acute on chronic liver failure (ACLF) versus standard of care (SOC) (ALIVER Consortium). Gut 70 (Suppl. 3), A54 (2021).
Simón-Talero, M. et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J. Hepatol. 59, 1184–1192 (2013).
Sharma, B. C. et al. Randomized controlled trial comparing lactulose plus albuminversuslactulose alone for treatment of hepatic encephalopathy. J. Gastroenterol. Hepatol. 32, 1234–1239 (2017).
Ventura-Cots, M. et al. Effects of albumin on survival after a hepatic encephalopathy episode: randomized double-blind trial and meta-analysis. J. Clin. Med. 10, 4885 (2021).
Sundaram, V. et al. Longterm outcomes of patients undergoing liver transplantation for acute-on-chronic liver failure. Liver Transplant. 26, 1594–1602 (2020).
European Association for the Study of the Liver. EASL clinical practice guidelines: liver transplantation. J. Hepatol. 64, 433–485 (2016).
Kamath, P. S. et al. A model to predict survival in patients with end-stage liver disease. Hepatology 33, 464–470 (2001).
Sundaram, V. et al. Patients with severe acute-on-chronic liver failure are disadvantaged by model for end-stage liver disease-based organ allocation policy. Aliment. Pharmacol. Ther. 52, 1204–1213 (2020).
Sotil, E. U., Gottstein, J., Ayala, E., Randolph, C. & Blei, A. T. Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation. Liver Transplant. 15, 184–192 (2009).
Garcia-Martinez, R. et al. Hepatic encephalopathy is associated with posttransplant cognitive function and brain volume. Liver Transplant. 17, 38–46 (2011).
Ochoa-Sanchez, R., Tamnanloo, F. & Rose, C. F. Hepatic encephalopathy: from metabolic to neurodegenerative. Neurochem. Res. 46, 2612–2625 (2021).
Younossi, Z. M. et al. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am. J. Gastroenterol. 96, 2199–2205 (2001).
Afendy, A. et al. Predictors of health-related quality of life in patients with chronic liver disease. Aliment. Pharmacol. Ther. 30, 469–476 (2009).
Montagnese, S. & Bajaj, J. S. Impact of hepatic encephalopathy in cirrhosis on quality-of-life issues. Drugs 79, 11–16 (2019).
Rabiee, A. et al. Factors associated with health-related quality of life in patients with cirrhosis: a systematic review. Liver Int. 41, 6–15 (2020).
Prasad, S. et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45, 549–559 (2007).
Agrawal, S., Umapathy, S. & Dhiman, R. K. Minimal hepatic encephalopathy impairs quality of life. J. Clin. Exp. Hepatol. 5, S42–S48 (2015).
Groeneweg, M. et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 28, 45–49 (1998).
Sidhu, S. S. et al. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (The RIME Trial). Am. J. Gastroenterol. 106, 307–316 (2011).
De Rui, M. et al. Excessive daytime sleepiness and hepatic encephalopathy: it is worth asking. Metab. Brain Dis. 28, 245–248 (2012).
Montagnese, S., Middleton, B., Skene, D. J. & Morgan, M. Y. Night-time sleep disturbance does not correlate with neuropsychiatric impairment in patients with cirrhosis. Liver Int. 29, 1372–1382 (2009).
Montagnese, S. et al. Sleep-wake abnormalities in patients with cirrhosis. Hepatology 59, 705–712 (2013).
Samanta, J. et al. Correlation between degree and quality of sleep disturbance and the level of neuropsychiatric impairment in patients with liver cirrhosis. Metab. Brain Dis. 28, 249–259 (2013).
Román, E. et al. Minimal hepatic encephalopathy is associated with falls. Am. J. Gastroenterol. 106, 476–482 (2011).
Soriano, G. et al. Cognitive dysfunction in cirrhosis is associated with falls: a prospective study. Hepatology 55, 1922–1930 (2012).
Diamond, T. et al. Osteoporosis and skeletal fractures in chronic liver disease. Gut 31, 82–87 (1990).
Bajaj, J. S. et al. Minimal hepatic encephalopathy and mild cognitive impairment worsen quality of life in elderly patients with cirrhosis. Clin. Gastroenterol. Hepatol. 18, 3008–3016.e2 (2020).
Wang, J. Y. et al. Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: a multicenter, randomized controlled trial. J. Dig. Dis. 20, 547–556 (2019).
Bruyneel, M. et al. Improvement of sleep architecture parameters in cirrhotic patients with recurrent hepatic encephalopathy with the use of rifaximin. Eur. J. Gastroenterol. Hepatol. 29, 302–308 (2017).
Sack, J. & Hashemi, N. Smartphone-based remote health monitoring-implications for healthcare delivery in patients with cirrhosis. J. Gen. Intern. Med. 34, 2726–2727 (2019).
Romero-Gómez, M. Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis. Ann. Intern. Med. 153, 281 (2010).
Yokoyama, K. et al. Hydrogen-producing small intestinal bacterial overgrowth is associated with hepatic encephalopathy and liver function. PLoS ONE 17, e0264459 (2022).
Rush, B. et al. Lower 90-day hospital readmission rates for esophageal variceal bleeding after TIPS: a nationwide linked analysis. J. Clin. Gastroenterol. 54, 90–95 (2020).
Labenz, C. et al. Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis. Aliment. Pharmacol. Ther. 52, 527–536 (2020).
Häussinger, D., Görg, B., Reinehr, R. & Schliess, F. Protein tyrosine nitration in hyperammonemia and hepatic encephalopathy. Metab. Brain Dis. 20, 285–294 (2005).
Brenner, M. et al. Patients with manifest hepatic encephalopathy can reveal impaired thermal perception. Acta Neurol. Scand. 132, 156–163 (2015).
Götz, T. et al. Impaired evoked and resting-state brain oscillations in patients with liver cirrhosis as revealed by magnetoencephalography. NeuroImage Clin. 2, 873–882 (2013).
Oeltzschner, G. et al. Low visual cortex GABA levels in hepatic encephalopathy: links to blood ammonia, critical flicker frequency, and brain osmolytes. Metab. Brain Dis. 30, 1429–1438 (2015).
Zöllner, H. J. et al. Chemical exchange saturation transfer imaging in hepatic encephalopathy. NeuroImage Clin. 22, 101743 (2019).
Schomerus, H. et al. Latent portasystemic encephalopathy. Dig. Dis. Sci. 26, 622–630 (1981).
Watanabe, A., Tuchida, T., Yata, Y. & Kuwabara, Y. Evaluation of neuropsychological function in patients with liver cirrhosis with special reference to their driving ability. Metab. Brain Dis. 10, 239–248 (1995).
Wein, C., Koch, H., Popp, B., Oehler, G. & Schauder, P. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 39, 739–745 (2004).
Marottoli, R. A. Predictors of automobile crashes and moving violations among elderly drivers. Ann. Intern. Med. 121, 842 (1994).
Bajaj, J. S., Hafeezullah, M., Hoffmann, R. G. & Saeian, K. Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am. J. Gastroenterol. 102, 1903–1909 (2007).
Bajaj, J. S., Saeian, K., Hafeezullah, M., Hoffmann, R. G. & Hammeke, T. A. Patients with minimal hepatic encephalopathy have poor insight into their driving skills. Clin. Gastroenterol. Hepatol. 6, 1135–1139 (2008).
Srivastava, A., Mehta, R., Rothke, S. P., Rademaker, A. W. & Blei, A. T. Fitness to drive in patients with cirrhosis and portal-systemic shunting: a pilot study evaluating driving performance. J. Hepatol. 21, 1023–1028 (1994).
Subasinghe, S. K. C. E. et al. Association between road accidents and low-grade hepatic encephalopathy among Sri Lankan drivers with cirrhosis: a prospective case control study. BMC Res. Notes 9, 303 (2016).
Bajaj, J. S. et al. Important unresolved questions in the management of hepatic encephalopathy: an ISHEN consensus. Am. J. Gastroenterol. 115, 989–1002 (2020).
D.H. and G.K. are members of the “Flicker Diagnostics GbR”. The S.M. group has received research funding from AlfaSigma S.p.a., Norgine Ltd., Merz Pharmaceuticals GmbH, Umecrine Cognition AB and Versantis AG. R.J. has research collaborations with Yaqrit Ltd. and Takeda. R.J. is the inventor of OPA, which has been patented by University College London and licensed to Mallinckrodt Pharma. He is also the founder of Yaqrit Ltd., a spin-out company from University College London, Cyberliver Ltd. and Hepyx Ltd. S.D.T.-R., B.G., M.R.-G., M.M., R.K.D., H.V., A.S. and V.F. declare no competing interests.
Peer review information
Nature Reviews Disease Primers thanks Patrick Kamath, Naveen Nasser-Ghodsi and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Häussinger, D., Dhiman, R.K., Felipo, V. et al. Hepatic encephalopathy. Nat Rev Dis Primers 8, 43 (2022). https://doi.org/10.1038/s41572-022-00366-6
This article is cited by
The role of brain inflammation and abnormal brain oxygen homeostasis in the development of hepatic encephalopathy
Metabolic Brain Disease (2022)
Neurochemical Research (2022)